Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $7 to $8.
Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $8...
Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, o...
Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $7 price target.
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) ...
